Bicycle Therapeutics/$BCYC

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Bicycle Therapeutics

Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.

Ticker

$BCYC
Primary listing

Industry

Biotechnology

Employees

305

ISIN

US0887861088

BCYC Metrics

BasicAdvanced
$513M
-
-$3.13
1.47
-

What the Analysts think about BCYC

Analyst ratings (Buy, Hold, Sell) for Bicycle Therapeutics stock.

Bulls say / Bears say

Barclays has maintained a 'Buy' rating for Bicycle Therapeutics with a price target of $40.00, indicating confidence in the company's growth prospects. (Markets Insider)
Bicycle Therapeutics has secured approximately $555 million through PIPE financing, extending its financial runway into the second half of 2027, which supports ongoing research and development efforts. (Investing.com)
The company is expected to release more data updates in the second half of 2024, including information on Zelenectide Pevedotin in combination with pembrolizumab for first-line metastatic urothelial carcinoma treatment, as well as monotherapy in late-line triple-negative breast cancer and non-small cell lung cancer, which could positively impact stock performance. (Investing.com)
Bicycle Therapeutics' stock reached a 52-week low of $14.81, reflecting potential investor concerns about the company's short-term performance. (Investing.com)
B. Riley Securities downgraded Bicycle Therapeutics, anticipating muted stock movement from upcoming data readouts, suggesting potential challenges in meeting market expectations. (Seeking Alpha)
Leerink Partners issued a negative outlook for Bicycle Therapeutics' earnings, indicating concerns about the company's financial performance. (ETF Daily News)
Data summarised monthly by Lightyear AI. Last updated on 5 Jun 2025.

BCYC Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

BCYC Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $BCYC

Sign up or log in to buy
Capital at risk
Market openADR

Upcoming events

No upcoming events
FAQs